🟢 Milestone Pharmaceuticals is trading 5.7% up today as traders reassess last week's post-earnings selloff

Milestone Pharmaceuticals is trading at $1.25 (5.7%) up today as shares stage a recovery following a significant selloff triggered by last week's Q1 earnings report.

• The stock faced heavy pressure last week after missing revenue and EPS estimates, which the company tied to the early-stage launch of its CARDAMYST treatment.
• Today's pre-market rebound occurs despite no new company-specific news, suggesting a technical recovery as investors reassess the recent sharp decline.
• Market focus remains on the commercial rollout of CARDAMYST, which continues to be the primary driver of the stock's recent volatility.